Literature DB >> 11601935

Guidelines for the management of patients with chronic stable angina: treatment.

S D Fihn1, S V Williams, J Daley, R J Gibbons.   

Abstract

The dual aims of treating patients with chronic stable angina are 1) to reduce morbidity and mortality and 2) to eliminate angina with minimal adverse effects and allow the patient to return to normal activities. In the absence of contraindications, beta-blockers are recommended as initial therapy. All beta-blockers seem to be equally effective. If the patient has serious contraindications to beta-blockers, unacceptable side effects, or persistent angina, calcium antagonists should be administered. Long-acting dihydropyridine and nondihydropyridine agents are generally as effective as beta-blockers in relieving angina. Long-acting nitrates are considered third-line therapy because a nitrate-free interval is required to avoid developing tolerance. All long-acting nitrates seem to be equally effective. Patients with angina should take 75 to 325 mg of aspirin daily unless they have contraindications. Such risk factors as smoking, elevated low-density lipoprotein cholesterol level, diabetes, and hypertension should be treated appropriately. Coronary revascularization has not been shown to improve survival for most patients with chronic angina but may be required to control symptoms. However, coronary artery bypass grafting (CABG) is often indicated for symptomatic patients with left-main disease, three-vessel disease, or two-vessel disease including proximal stenosis of the left anterior descending coronary artery; it improves their survival. Percutaneous transluminal coronary angioplasty is an alternative to CABG for patients with normal left ventricular function and favorable angiographic features. Coronary artery bypass grafting is initially more effective in relieving angina than medical therapy, but the two procedures yield similar results after 5 to 10 years. Eighty percent of patients who undergo CABG remain angina-free 5 years after surgery. In low-risk patients, percutaneous transluminal coronary angioplasty seems to control angina better than medical therapy, but recurrent angina and repeated procedures are more likely than with CABG. Patient education is an important component of management. Long-term follow-up should be individualized to ascertain clinical stability at regular intervals and to reassess prognosis when warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11601935     DOI: 10.7326/0003-4819-135-8_part_1-200110160-00014

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  [Benefits and risks of nitrate preparations in the treatment of angina pectoris].

Authors:  S Rosenkranz; E Erdmann
Journal:  Internist (Berl)       Date:  2005-06       Impact factor: 0.743

Review 2.  Ranolazine: a review of its use in chronic stable angina pectoris.

Authors:  M Asif A Siddiqui; Susan J Keam
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Treatment of stable angina.

Authors:  Itsik Ben-Dor; Alexander Battler
Journal:  Heart       Date:  2007-07       Impact factor: 5.994

4.  Secondary prevention in coronary heart disease: goal achievement and drug prescribing.

Authors:  Trude Giverhaug; Christine Bruland; Thor Trovik
Journal:  Pharm World Sci       Date:  2005-12

5.  Trapidil is as effective as isosorbide-dinitrate for treating stable angina pectoris: a multinational, multicenter, double-blind, randomized study.

Authors:  T Meinertz; W Lehmacher
Journal:  Clin Res Cardiol       Date:  2006-03-22       Impact factor: 5.460

6.  Comparison of diagnostic performance between quantitative flow ratio, non-hyperemic pressure indices and fractional flow reserve.

Authors:  Ojas Hrakesh Mehta; Michael Hay; Ren Yik Lim; Abdul Rahman Ihdayhid; Michael Michail; Jun Michael Zhang; James D Cameron; Dennis T L Wong
Journal:  Cardiovasc Diagn Ther       Date:  2020-06

7.  Absence of respiratory effects with ivabradine in patients with asthma.

Authors:  K Suresh Babu; Frantisek Gadzik; Stephen T Holgate
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

8.  Enhanced External Counterpulsation (EECP): An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-03-01

Review 9.  Beta-blockers after acute myocardial infarction in elderly patients with diabetes mellitus: time to reassess.

Authors:  Mauro Di Bari; Niccolò Marchionni; Marco Pahor
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Reasons for overprescription of mononitrates: the paradigm of stable angina pectoris treatment.

Authors:  Mickie Preis; Ronit Peled; Matityhau Lifshitz; Asher Elhayani; Asaf Toker; Haim Reuveni
Journal:  Curr Ther Res Clin Exp       Date:  2003-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.